PAREXEL International Corporation (PRXL) : Roanoke Asset Management Corp Ny reduced its stake in PAREXEL International Corporation by 29.05% during the most recent quarter end. The investment management company now holds a total of 51,046 shares of PAREXEL International Corporation which is valued at $3,385,371 after selling 20,904 shares in PAREXEL International Corporation , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.PAREXEL International Corporation makes up approximately 1.49% of Roanoke Asset Management Corp Ny’s portfolio.
Other Hedge Funds, Including , Spot Trading L.l.c added PRXL to its portfolio by purchasing 9,726 company shares during the most recent quarter which is valued at $645,028. PAREXEL International Corporation makes up approx 0.09% of Spot Trading L.l.c’s portfolio.Aberdeen Asset Management Plcuk boosted its stake in PRXL in the latest quarter, The investment management firm added 201,812 additional shares and now holds a total of 998,811 shares of PAREXEL International Corporation which is valued at $66,241,146. PAREXEL International Corporation makes up approx 0.24% of Aberdeen Asset Management Plcuk’s portfolio.Msi Financial Services Inc boosted its stake in PRXL in the latest quarter, The investment management firm added 624 additional shares and now holds a total of 1,440 shares of PAREXEL International Corporation which is valued at $94,334.Capstone Asset Management Co boosted its stake in PRXL in the latest quarter, The investment management firm added 740 additional shares and now holds a total of 5,949 shares of PAREXEL International Corporation which is valued at $392,991. PAREXEL International Corporation makes up approx 0.01% of Capstone Asset Management Co’s portfolio.
PAREXEL International Corporation closed down -1.11 points or -1.61% at $67.9 with 3,91,315 shares getting traded on Monday. Post opening the session at $68.76, the shares hit an intraday low of $67.76 and an intraday high of $69 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, PAREXEL International Corporation reported $0.94 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.93. The company had revenue of $538.60 million for the quarter, compared to analysts expectations of $532.59 million. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 EPS.
Many Wall Street Analysts have commented on PAREXEL International Corporation. Credit Suisse Initiated PAREXEL International Corporation on Jun 21, 2016 to “Outperform”, Price Target of the shares are set at $75.
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.